ViroXis Corporation, Inc., (San Antonio, TX) is a mid-stage drug development company formed around the in-licensing of a clinical stage drug candidate that contains a well characterized botanical extract. ViroXis Corporation is developing a unique range of patented, effective, and very well tolerated botanical anti-viral topical prescription drug candidates to treat diseases of the skin, such as HPV (skin and genital warts), Pox virus (Molluscum contagiosum), and Herpes (cold sores and shingles). The company's drug candidates are being developed under the FDA's 2004 botanical guidelines, with a lead product for common HPV skin warts in an FDA Phase 2 study, with a Phase 2 study for Molluscum contagiousum to begin mid 2014.
TFS to acquire US pharmaceutical partners to capture downstream revenues from product sales.
